Daniel Densham founded Medical Biosystems in 1997 while at University.
Mobious Biosystems was founded by Daniel Densham at the end of 1999, with venture funding.
He conceived the technology underpinning Molecular Resonance Sequencing ahead of his medical studies at Guy’s, Kings and St.Thomas’s Medical and Dental School in London, UK.
During his medical studies, it struck him that the unification of natural cellular replication systems and artificial nanostructures could have a dramatic impact on DNA sequencing and healthcare generally. He filed the first technology defining patent in the UK in July 1997 and founded Medical Biosystems Ltd, holding the intellectual property exclusively licensed to Mobious Genomics.
These patented systems involve the use of immbolised polymerases within differing kinds of electromagnetic field. This approach inherently increases the platform’s signal-to-noise ratio as well as allowing real-time read out. In the case of polynucleotide sequencing, this allow real-time monitoring of polymerases activity, and thus sequence data is derived in real-time. This has significant advantages over traditional “short read” technologies, notably read length (and thus a huge reduction in computational load required for reassembly) as well as sensitivity to “unusual” base substrates . e.g. methylated bases. The methylation status of bases within humans and of other biological systems has been shown to be extremely important in terms of gene expression. Cancer and infectious diseases are notable examples. Again, this technology is applicable at both the single and multi molecule levels as well as labelled and unlabelled embodiments. This makes the associated embodiment’s extremely powerful tools for use in Precision Medicine and Genomics in general.
Mobious Genomics established molecular biology and bionanotechnology laboratory facilities on the campus of the University of Exeter, UK. This provided ready access to the University’s bioinformatics capabilities as well as the School of Biological Sciences and the Peninsular Medical school. The University of Exeter awarded Daniel an honorary research fellowship in the Department of Diabetes and Vascular medicine at the University of Exeter in recognition of his work.
Molecular Research Limited (MRL) was founded by Daniel Densham in 2011 to continue his groundbreaking work in Next Generation Molecular Platforms. These include, Third, Forth and Fifth generation sequencing systems, Next generation labelled and label free Proteomics Platforms, both at the single and multi-molecule levels.
Daniel and MRL are committed to the development of solutions for the analysis and treatment of disease.
Please check back for further information on our IP and technology platform status.